The protective role of lutein on isoproterenol-induced cardiac failure rat model through improving cardiac morphology, antioxidant status via positively regulating Nrf2/HO-1 signalling pathway

Context: Lutein (LU) is a major carotenoid with various pharmacological activities including anti-inflammatory, antioxidant and anti-apoptosis. Objective: The cardioprotective efficacy of LU was determined by evaluating the biochemical and histopathological changes in isoproterenol (ISO) induced myo...

Full description

Bibliographic Details
Main Authors: Bo Ouyang, Zili Li, Xiongying Ji, Jiangwei Huang, Hengsheng Zhang, Changrong Jiang
Format: Article
Language:English
Published: Taylor & Francis Group 2019-01-01
Series:Pharmaceutical Biology
Subjects:
Online Access:http://dx.doi.org/10.1080/13880209.2019.1649436
id doaj-ff9d24e775c94fb394d567e9e19f48d2
record_format Article
spelling doaj-ff9d24e775c94fb394d567e9e19f48d22020-11-25T03:08:26ZengTaylor & Francis GroupPharmaceutical Biology1388-02091744-51162019-01-0157152953510.1080/13880209.2019.16494361649436The protective role of lutein on isoproterenol-induced cardiac failure rat model through improving cardiac morphology, antioxidant status via positively regulating Nrf2/HO-1 signalling pathwayBo Ouyang0Zili Li1Xiongying Ji2Jiangwei Huang3Hengsheng Zhang4Changrong Jiang5Affiliated Nanhua Hospital, University of South ChinaAffiliated Nanhua Hospital, University of South ChinaAffiliated Nanhua Hospital, University of South ChinaAffiliated Nanhua Hospital, University of South ChinaAffiliated Nanhua Hospital, University of South ChinaAffiliated Nanhua Hospital, University of South ChinaContext: Lutein (LU) is a major carotenoid with various pharmacological activities including anti-inflammatory, antioxidant and anti-apoptosis. Objective: The cardioprotective efficacy of LU was determined by evaluating the biochemical and histopathological changes in isoproterenol (ISO) induced myocardial infarction (MI) rat model. Materials and methods: Healthy male albino rats (n = 40) were segregated into 4 equal groups. Group I (control) rats were administered with olive oil, Group II (LU) rats were orally pre-treated with only 40 mg of LU for 28 days, Group III (MI induced) rats were injected (subcutaneously; s.c) with 85 mg/kg of ISO for 2 consecutive days, whereas Group IV (LU + ISO) rats were pre-treated with 40 mg of LU for 28 days before ISO induction. Results: ISO-induced group showed increased infarct size and cardiac/inflammatory/apoptotic markers. However, pre-treatment with LU (28 days) considerably reduced (p < 0.01) the infarct size (14%), lipid peroxidation product (MDA;42%), cardiac markers [(lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB), cardiac troponin T (cTn T)], inflammatory markers [IL-1β, IL-6, tumour necrosis factor alpha (TNF-α), nuclear factor kappa B p65 subunit (NF-κB p65)] and apoptotic markers (caspase-3 and -9). Also, LU significantly improved (p < 0.01) the antioxidants [catalase (CAT), superoxide dismutase (SOD)] as well as markedly upregulated (p < 0.01) the protein expression of HO-1 and Nrf2. Moreover, LU considerably reversed all the histopathological changes and thus exhibits its cardioprotective activity. Conclusion: LU exhibits potent cardioprotective activity against ISO-induced cardiotoxicity and might be recommended with standard cardioprotective agents for treating various MI-related complications.http://dx.doi.org/10.1080/13880209.2019.1649436myocardial infarctioninfarct sizecardioprotectivecardiac markers
collection DOAJ
language English
format Article
sources DOAJ
author Bo Ouyang
Zili Li
Xiongying Ji
Jiangwei Huang
Hengsheng Zhang
Changrong Jiang
spellingShingle Bo Ouyang
Zili Li
Xiongying Ji
Jiangwei Huang
Hengsheng Zhang
Changrong Jiang
The protective role of lutein on isoproterenol-induced cardiac failure rat model through improving cardiac morphology, antioxidant status via positively regulating Nrf2/HO-1 signalling pathway
Pharmaceutical Biology
myocardial infarction
infarct size
cardioprotective
cardiac markers
author_facet Bo Ouyang
Zili Li
Xiongying Ji
Jiangwei Huang
Hengsheng Zhang
Changrong Jiang
author_sort Bo Ouyang
title The protective role of lutein on isoproterenol-induced cardiac failure rat model through improving cardiac morphology, antioxidant status via positively regulating Nrf2/HO-1 signalling pathway
title_short The protective role of lutein on isoproterenol-induced cardiac failure rat model through improving cardiac morphology, antioxidant status via positively regulating Nrf2/HO-1 signalling pathway
title_full The protective role of lutein on isoproterenol-induced cardiac failure rat model through improving cardiac morphology, antioxidant status via positively regulating Nrf2/HO-1 signalling pathway
title_fullStr The protective role of lutein on isoproterenol-induced cardiac failure rat model through improving cardiac morphology, antioxidant status via positively regulating Nrf2/HO-1 signalling pathway
title_full_unstemmed The protective role of lutein on isoproterenol-induced cardiac failure rat model through improving cardiac morphology, antioxidant status via positively regulating Nrf2/HO-1 signalling pathway
title_sort protective role of lutein on isoproterenol-induced cardiac failure rat model through improving cardiac morphology, antioxidant status via positively regulating nrf2/ho-1 signalling pathway
publisher Taylor & Francis Group
series Pharmaceutical Biology
issn 1388-0209
1744-5116
publishDate 2019-01-01
description Context: Lutein (LU) is a major carotenoid with various pharmacological activities including anti-inflammatory, antioxidant and anti-apoptosis. Objective: The cardioprotective efficacy of LU was determined by evaluating the biochemical and histopathological changes in isoproterenol (ISO) induced myocardial infarction (MI) rat model. Materials and methods: Healthy male albino rats (n = 40) were segregated into 4 equal groups. Group I (control) rats were administered with olive oil, Group II (LU) rats were orally pre-treated with only 40 mg of LU for 28 days, Group III (MI induced) rats were injected (subcutaneously; s.c) with 85 mg/kg of ISO for 2 consecutive days, whereas Group IV (LU + ISO) rats were pre-treated with 40 mg of LU for 28 days before ISO induction. Results: ISO-induced group showed increased infarct size and cardiac/inflammatory/apoptotic markers. However, pre-treatment with LU (28 days) considerably reduced (p < 0.01) the infarct size (14%), lipid peroxidation product (MDA;42%), cardiac markers [(lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB), cardiac troponin T (cTn T)], inflammatory markers [IL-1β, IL-6, tumour necrosis factor alpha (TNF-α), nuclear factor kappa B p65 subunit (NF-κB p65)] and apoptotic markers (caspase-3 and -9). Also, LU significantly improved (p < 0.01) the antioxidants [catalase (CAT), superoxide dismutase (SOD)] as well as markedly upregulated (p < 0.01) the protein expression of HO-1 and Nrf2. Moreover, LU considerably reversed all the histopathological changes and thus exhibits its cardioprotective activity. Conclusion: LU exhibits potent cardioprotective activity against ISO-induced cardiotoxicity and might be recommended with standard cardioprotective agents for treating various MI-related complications.
topic myocardial infarction
infarct size
cardioprotective
cardiac markers
url http://dx.doi.org/10.1080/13880209.2019.1649436
work_keys_str_mv AT boouyang theprotectiveroleofluteinonisoproterenolinducedcardiacfailureratmodelthroughimprovingcardiacmorphologyantioxidantstatusviapositivelyregulatingnrf2ho1signallingpathway
AT zilili theprotectiveroleofluteinonisoproterenolinducedcardiacfailureratmodelthroughimprovingcardiacmorphologyantioxidantstatusviapositivelyregulatingnrf2ho1signallingpathway
AT xiongyingji theprotectiveroleofluteinonisoproterenolinducedcardiacfailureratmodelthroughimprovingcardiacmorphologyantioxidantstatusviapositivelyregulatingnrf2ho1signallingpathway
AT jiangweihuang theprotectiveroleofluteinonisoproterenolinducedcardiacfailureratmodelthroughimprovingcardiacmorphologyantioxidantstatusviapositivelyregulatingnrf2ho1signallingpathway
AT hengshengzhang theprotectiveroleofluteinonisoproterenolinducedcardiacfailureratmodelthroughimprovingcardiacmorphologyantioxidantstatusviapositivelyregulatingnrf2ho1signallingpathway
AT changrongjiang theprotectiveroleofluteinonisoproterenolinducedcardiacfailureratmodelthroughimprovingcardiacmorphologyantioxidantstatusviapositivelyregulatingnrf2ho1signallingpathway
AT boouyang protectiveroleofluteinonisoproterenolinducedcardiacfailureratmodelthroughimprovingcardiacmorphologyantioxidantstatusviapositivelyregulatingnrf2ho1signallingpathway
AT zilili protectiveroleofluteinonisoproterenolinducedcardiacfailureratmodelthroughimprovingcardiacmorphologyantioxidantstatusviapositivelyregulatingnrf2ho1signallingpathway
AT xiongyingji protectiveroleofluteinonisoproterenolinducedcardiacfailureratmodelthroughimprovingcardiacmorphologyantioxidantstatusviapositivelyregulatingnrf2ho1signallingpathway
AT jiangweihuang protectiveroleofluteinonisoproterenolinducedcardiacfailureratmodelthroughimprovingcardiacmorphologyantioxidantstatusviapositivelyregulatingnrf2ho1signallingpathway
AT hengshengzhang protectiveroleofluteinonisoproterenolinducedcardiacfailureratmodelthroughimprovingcardiacmorphologyantioxidantstatusviapositivelyregulatingnrf2ho1signallingpathway
AT changrongjiang protectiveroleofluteinonisoproterenolinducedcardiacfailureratmodelthroughimprovingcardiacmorphologyantioxidantstatusviapositivelyregulatingnrf2ho1signallingpathway
_version_ 1715295783093272576